Many.prostate cancers that are usually diagnosed in older men are slow growing and not considered fatal. But some become aggressive and spread beyond the prostate, making them difficult to treat and life-threatening. With current knowledge doctors are unable to determine which will be slow growing and which will spread to other sites. In this study published recently in Clinical Cancer Research report discovering a genetic signature .within prostate cancer that can predict which tumors are likely to metastasize.
Using several data sets of prostate cancer patients and outcomes researchers found that a high number expressed two genes: TOP2A and EZH2 were associated with early recurrence of prostate cancer and metastatic spread leading to an increased risk of death. Strong metastatic tendencies were only expressed if both genes were found in the tumor. Researchers said: “Altogether we found that high levels of TOP2A and EZH2 expression consistently associated in the progression to a metastatic and lethal disease. “
Using mouse prostate cancer cells in the lab, researchers found that cells containing overexposed TOP2A and EZH2 genes were highly sensitive to attack with a combination of 2 drugs. However, clinical trials are necessary to make a definitive statement. It is hoped that attacking these genes with drugs may prevent aggressive cells from p metastasizing. .